{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T09:40:49Z","timestamp":1698831649110},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,12,4]],"date-time":"2011-12-04T00:00:00Z","timestamp":1322956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytopathology"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>S. S. Hoo, A. Patel, H. Buist, K. Galaal, J. D. Hemming and R. Naik<\/jats:p><jats:p><jats:bold>Borderline nuclear change, high\u2010grade dyskaryosis not excluded: current concepts and impact on clinical practice<\/jats:bold><\/jats:p><jats:p><jats:bold>Objective:\u2002<\/jats:bold> Borderline nuclear change, high\u2010grade dyskaryosis not excluded (B\/HG) is a subcategory of the borderline category recommended by the British Society for Clinical Cytology as warranting direct referral to colposcopy. This subcategory is equivalent to the Bethesda category of atypical squamous cells, cannot exclude high\u2010grade squamous intraepithelial lesion (ASC\u2010H). The purpose of this study was to determine the validity and accuracy of using B\/HG to identify potential cervical intraepithelial neoplasia (CIN) grade 2 or worse (CIN2+).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Data were collected from the hospital pathology database for borderline, B\/HG and high\u2010grade cytology (moderate dyskaryosis and above), and their respective histological and colposcopic outcomes. SPSS was used for data analysis.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Of the 84 799 total cytology samples screened between July 2006 and December 2009, 5225 (6.1%) were reported as borderline, 309 (0.4%) as B\/HG and 1222 (1.4%) as high\u2010grade cytology. Thus, B\/HG comprised 5.9% of the overall borderline category, in keeping with national guidelines (&lt;10%). CIN2+ was confirmed in 86.6% of high\u2010grade, 40.8% of B\/HG and 3.0% of borderline cytology. Of 309 women reported with B\/HG cytology, 239 had colposcopy. Colposcopic appearances showed a positive predictive value (PPV) of 71.8% for detecting CIN2+ and a negative predictive value of 60.7%.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> The B\/HG category was associated with a significantly higher incidence of CIN2+ compared with borderline cytology as a whole. This refining performance justifies its existence. Colposcopic appearances had a high PPV for detecting CIN2+. Therefore, colposcopy is recommended in patients with B\/HG cytology and treatment should be offered if high\u2010grade colposcopic changes are seen.<\/jats:p>","DOI":"10.1111\/j.1365-2303.2011.00943.x","type":"journal-article","created":{"date-parts":[[2011,12,5]],"date-time":"2011-12-05T02:00:08Z","timestamp":1323050408000},"page":"396-401","source":"Crossref","is-referenced-by-count":1,"title":["Borderline nuclear change, high\u2010grade dyskaryosis not excluded: current concepts and impact on clinical practice"],"prefix":"10.1111","volume":"23","author":[{"given":"S.","family":"Soo Hoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Buist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Galaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Hemming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2008.00585.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.39.9.933"},{"key":"e_1_2_5_4_2","first-page":"335","article-title":"\u201cASCUS, rule out HSIL\u201d: cytologic features, histologic correlates, and human papillomavirus detection","volume":"12","author":"Sherman ME","year":"1999","journal-title":"Mod Pathol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.6.481"},{"key":"e_1_2_5_6_2","unstructured":"NHS Cervical Screening Programme.Achievable standards benchmarks for reporting and criteria for evaluating cervical cytopathology:JohnsonJ PatnickJ(eds).NHSCSP Publication No. 1 Sheffield United Kingdom: NHSCSP Publications May2000."},{"key":"e_1_2_5_7_2","volume-title":"Cervical Screening Programme England, 2009\u20132010","author":"NHS","year":"2010"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2303.2002.00395.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.52.10.787"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2003.00118.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1309\/NQ0U-T0YC-TLHD-TTKX"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2006.00395.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2114"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(16)32330-1"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1309\/NPU3WRQCTAB81XLW"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1309\/JM3V-U4HP-W8HJ-68XV"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6413-4-7"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20052"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21387"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/dc.20227"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21388"},{"key":"e_1_2_5_22_2","unstructured":"NHS Cervical Screening Programme.Report to the Department of Health on evaluation of HPV\/LBC Cervical Pilot Studies:MossSM GrayA MarteauT LegoodR HenstockE MaissiE. Cancer Screening Evaluation Unit Institute of Cancer Research Surrey UK. October2004."},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.326"}],"container-title":["Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2303.2011.00943.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2303.2011.00943.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:59:54Z","timestamp":1698735594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2303.2011.00943.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,4]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1111\/j.1365-2303.2011.00943.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2303.2011.00943.x","archive":["Portico"],"relation":{},"ISSN":["0956-5507","1365-2303"],"issn-type":[{"value":"0956-5507","type":"print"},{"value":"1365-2303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,4]]}}}